Newtyn Management’s CytomX Therapeutics CTMX Stock Holding History

Newtyn Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-425,000	Closed	-$642K	–	56
2023 Q1	$642K	Sell	425,000 -145,000	-25%	-$328K	0.13%	64
2022 Q4	$912K	Sell	570,000 -230,000	-29%	-$340K	0.19%	55
2022 Q3	$1.16M	Sell	800,000 -273,400	-25%	-$421K	0.25%	48
2022 Q2	$1.96M	Buy	+1,073,400	New	+$2.06M	0.37%	42

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Newtyn Management's CTMX Position: Q2 2023 in Review

Newtyn Management sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 425,000 shares — an estimated $642K sold.

Newtyn Management first reported a position in CTMX in Q2 2022 and held it in 4 quarters. The position peaked at $1.96M in Q2 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

Newtyn Management reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
Newtyn Management sold 425,000 CytomX Therapeutics shares in Q2 2023, an estimated $642K.
Newtyn Management first reported a position in CytomX Therapeutics in Q2 2022 and held it in 4 quarters.
Newtyn Management's CytomX Therapeutics position peaked at $1.96M in Q2 2022.
67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.